BUSINESS● LOW3h ago · Oct 29, 2026, 6:00 PM
Alnylam anticipates $4.2B–$4.5B 2026 TTR sales, expands TRITON-CM to ~2,250 patients while keeping ~2030 launch timing
Seeking Alpha Tech · global
Alnylam anticipates $4.2B–$4.5B in TTR sales by 2026 and plans to expand its TRITON-CM program to approximately 2,250 patients, while maintaining a launch timing around 2030. This details the company's future financial projections and clinical development plans.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS30m agoReddit shares sink on weak sales guidance and plans login requirement test as Google search traffic shrinksCNBCBUSINESS31m agoSkyWest GAAP EPS of $3.08 misses by $0.14, revenue of $1.12B misses by $20MSeeking Alpha Tech